Global Cervical Cancer Vaccines Market, by Product Type (Cervarix, Gardasil, and Gardasil 9), by Distribution Channel (Hospitals, Clinics, and Government Entities), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2,595.5 million in 2018, and is projected to exhibit a CAGR of 12.1% over the forecast period (2019 - 2026), as highlighted in a new report published by . Increasing awareness amongst the population regarding cervical cancer and growing rate of unprotected sex in countries such as Swaziland, Malawi, and Zambia are some major factors driving the cervical cancer vaccines market growth. For instance, according to the World Cancer Research Fund (WCRF), Swaziland, Malawi, and Zambia are the top 3 countries in cervical cancer incidence. Moreover, cervical cancer can be prevented via widespread immunization with the HPV vaccine, which prevents infection from high-risk HPV strains and also offers protection against the low-risk ones, which cause genital warts. For instance, according to the Centers for Disease Control and Prevention (CDC), Human papilloma virus vaccines (HPV) can be administered to girls failing in the age group of 11 or 12 years. Moreover, cervical cancer vaccine at an early stage of life is highly effective. For instance, according to the CDC 2016, all teens and adolescents falling between the ages of 9 and 14 should receive two doses of HPV vaccination within a gap of six months. The global surge in the number of cervical cancer patients, especially in developing countries, led to development of new vaccines at a low cost. Most vaccines for cervical cancer are in their late stage of clinical development. For instance, ISA Pharmaceuticals B.V. is focused on manufacturing cervical cancer vaccine, ISA104 ( HPV16) and ISA104 ( HPV16) vaccines is under phase II trial of clinical development. Browse 23 Market Data Tables and 21 Figures spread through 145 Pages and in-depth TOC on "Cervical Cancer Vaccines Market, By Product Type (Cervarix, Gardasil, and Gardasil 9), By Distribution Channel (Hospitals, Clinics, and Government Entities), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026" To know the latest trends and insights related to cervical cancer vaccines market, click the link below: https://www.coherentmarketinsights.com/market-insight/cervical-cancer-vaccines-market-2931 Increasing awareness campaigns regarding HPV vaccination by governments and private NGOs is expected to boost the market growth. For instance, in 2013, 1.5 million girls were vaccinated with Gavi (The vaccines Alliance) support. Moreover, in 2017, Gavi helped 30 countries to conduct HPV vaccine demonstration programs. Key Takeaways of the cervical cancer vaccines market:
- The global cervical cancer vaccines market is expected to witness a CAGR of 12.1% during the forecast period (2019–2026), Owing to Increasing Awareness Regarding Cervical Cancers and Growing Rate of Unprotected Sex.
- Among product type, the Gardasil 9 segment is expected to account for a major revenue share in 2026. According to The Advisory Committee on Immunization Practices (ACIP) 2016, Gardasil 9 is the only HPV vaccine available in the U.S. and is recommended for vaccinating girls and boys between 11 and 12 years of age, before they become sexually active. Moreover, ACIP recommends an immunization schedule of two doses before the age of 14 and three doses after the age 14.
- Major players operating in the global cervical cancer vaccines market include, GlaxoSmithKline PLC and Merck & Co. Inc.
